Status:
RECRUITING
Molecular Profiling Project
Lead Sponsor:
National Cancer Centre, Singapore
Collaborating Sponsors:
Singapore General Hospital
Conditions:
Lung Cancer
Non-Small Cell Lung Cancer
Eligibility:
All Genders
21+ years
Brief Summary
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype i...
Detailed Description
ATORG is undertaking a comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype. These mutations are screened...
Eligibility Criteria
Inclusion
- The availability of sufficient archival tumor tissue specimen (15 slides of 4 microns per section)
- Age ≥ 21 years
- WHO performance status ≤ 2
- Life expectancy of ≥ 12 weeks
- Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
- Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL
- Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present)
- Willing to provide signed informed consent
- Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment
Exclusion
- \- No more than 3 lines of cytotoxic chemotherapy at the time of enrolment
Key Trial Info
Start Date :
January 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 25 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04025515
Start Date
January 11 2019
End Date
December 25 2025
Last Update
June 15 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
The Brunei Cancer Centre
Brunei, Brunei
2
Hong Kong Integrated Oncology Centre
Hong Kong, Hong Kong
3
The Chinese University of Hong Kong, Department of Clinical Oncology
Hong Kong, Hong Kong
4
Rajiv Ghandhi Cancer Institute and Research Centre
New Delhi, India